Abstract：
BACKGROUND: Paeoniae Radix Rubra (PRR) is the dried root of Paeonia lactiflora Pall, which has been widely used to anti-thrombotic, lipid-lowering, anti-spasmodic, antioxidant, antibacterial, hepatoprotective, and anti-tumor in Chinese clinical practice. Recent research has demonstrated that PRR plays a significant anti-tumor role in animal models of tumor-bearing.
OBJECTIVE: There has not been the evaluation of the anti-tumor effects of PRR. This study conducts a meta-analysis to assess the anti-tumor efficacy of PRR on animal models, providing scientific evidence for clinical application of PRR in the adjuvant therapy of tumors.
METHODS: English databases (PubMed, The Cochrane Library, Embase, and Web of Science) and Chinese databases (CNKI, WanFang, SinoMed, CTSJ-VIP) were used to search all pertinent animal studies investigating the anti-tumor effects of PRR and its extracts. The quality of the included studies was evaluated using the SYRCLE animal experiment risk assessment tool, and statistical analysis was carried out using Revman 5.3 software. Egger\'s test and funnel plots were used to assess potential publication bias in the studies.
RESULTS: The initial search produced a total of 3905 potentially pertinent studies, and 24 studies met the inclusion criteria. These studies included animal tumor models of hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. The meta-analysis findings demonstrated that both PRR and its extracts significantly inhibited tumor growth in animals. Compared with the control group, PRR substantively inhibited tumor volume (SMD, -3.09; 95% CI, [-4.05, -2.13]; P < 0.0001), reduced tumor weight (SMD, -1.08; 95% CI, [-1.37, -0.78]; P < 0.0001), decreased tumor number (SMD, -2.16; 95% CI, [-3.45, -0.86]; P = 0.001), and prolonged the survival duration time (SMD, 0.97; 95% CI, [0.23, 1.71]; P = 0.01) on the experimental animals.
CONCLUSIONS: PRR displayed a potential therapeutic efficacy on eight tumors in animal models including hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. However, the quality and quantity of included studies may affect the accuracy of positive results. In the future, more high-quality randomized controlled animal experiments are need for meta-analysis.
OBJECTIVE: There has not been the evaluation of the anti-tumor effects of PRR. This study conducts a meta-analysis to assess the anti-tumor efficacy of PRR on animal models, providing scientific evidence for clinical application of PRR in the adjuvant therapy of tumors.
METHODS: English databases (PubMed, The Cochrane Library, Embase, and Web of Science) and Chinese databases (CNKI, WanFang, SinoMed, CTSJ-VIP) were used to search all pertinent animal studies investigating the anti-tumor effects of PRR and its extracts. The quality of the included studies was evaluated using the SYRCLE animal experiment risk assessment tool, and statistical analysis was carried out using Revman 5.3 software. Egger\'s test and funnel plots were used to assess potential publication bias in the studies.
RESULTS: The initial search produced a total of 3905 potentially pertinent studies, and 24 studies met the inclusion criteria. These studies included animal tumor models of hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. The meta-analysis findings demonstrated that both PRR and its extracts significantly inhibited tumor growth in animals. Compared with the control group, PRR substantively inhibited tumor volume (SMD, -3.09; 95% CI, [-4.05, -2.13]; P < 0.0001), reduced tumor weight (SMD, -1.08; 95% CI, [-1.37, -0.78]; P < 0.0001), decreased tumor number (SMD, -2.16; 95% CI, [-3.45, -0.86]; P = 0.001), and prolonged the survival duration time (SMD, 0.97; 95% CI, [0.23, 1.71]; P = 0.01) on the experimental animals.
CONCLUSIONS: PRR displayed a potential therapeutic efficacy on eight tumors in animal models including hepatocellular carcinoma, lung cancer, sarcoma, bladder cancer, leukemia, colon cancer, glioblastoma, and pancreatic cancer. However, the quality and quantity of included studies may affect the accuracy of positive results. In the future, more high-quality randomized controlled animal experiments are need for meta-analysis.
摘要：
背景：赤芍（PRR）是白芍的干燥根，已被广泛用于抗血栓，降脂，抗痉挛,抗氧化剂，抗菌，保肝,和抗肿瘤在中国临床实践中的应用。最近的研究表明，PRR在荷瘤动物模型中起着重要的抗肿瘤作用。
目的：目前尚未评价PRR的抗肿瘤作用。这项研究进行了荟萃分析，以评估PRR在动物模型上的抗肿瘤功效。为PRR在肿瘤辅助治疗中的临床应用提供科学依据。
方法：英文数据库(PubMed，科克伦图书馆,Embase,和WebofScience)和中文数据库(CNKI，万方,SinoMed,CTSJ-VIP）用于搜索研究PRR及其提取物的抗肿瘤作用的所有相关动物研究。纳入研究的质量采用SYRCLE动物实验风险评估工具,采用Revman5.3软件进行统计学分析。Egger检验和漏斗图用于评估研究中潜在的发表偏倚。
结果：最初的搜索共产生了3905项潜在相关研究，24项研究符合纳入标准.这些研究包括肝细胞癌的动物肿瘤模型，肺癌,肉瘤,膀胱癌,白血病,结肠癌,胶质母细胞瘤,还有胰腺癌.荟萃分析结果表明，PRR及其提取物均显着抑制动物肿瘤的生长。与对照组相比,PRR实质性抑制肿瘤体积(SMD，-3.09；95%CI，[-4.05，-2.13]；P<0.0001），肿瘤重量降低（SMD，-1.08；95%CI，[-1.37，-0.78]；P<0.0001），肿瘤数量减少(SMD，-2.16；95%CI，[-3.45，-0.86]；P=0.001），并延长了生存持续时间(SMD，实验动物为0.97；95%CI，[0.23，1.71]；P=0.01）。
结论：PRR在包括肝细胞癌在内的8种动物模型中显示出潜在的治疗效果，肺癌,肉瘤,膀胱癌,白血病,结肠癌,胶质母细胞瘤,还有胰腺癌.然而,纳入研究的质量和数量可能会影响阳性结果的准确性.在未来,需要更多高质量的随机对照动物实验进行荟萃分析.
目的：目前尚未评价PRR的抗肿瘤作用。这项研究进行了荟萃分析，以评估PRR在动物模型上的抗肿瘤功效。为PRR在肿瘤辅助治疗中的临床应用提供科学依据。
方法：英文数据库(PubMed，科克伦图书馆,Embase,和WebofScience)和中文数据库(CNKI，万方,SinoMed,CTSJ-VIP）用于搜索研究PRR及其提取物的抗肿瘤作用的所有相关动物研究。纳入研究的质量采用SYRCLE动物实验风险评估工具,采用Revman5.3软件进行统计学分析。Egger检验和漏斗图用于评估研究中潜在的发表偏倚。
结果：最初的搜索共产生了3905项潜在相关研究，24项研究符合纳入标准.这些研究包括肝细胞癌的动物肿瘤模型，肺癌,肉瘤,膀胱癌,白血病,结肠癌,胶质母细胞瘤,还有胰腺癌.荟萃分析结果表明，PRR及其提取物均显着抑制动物肿瘤的生长。与对照组相比,PRR实质性抑制肿瘤体积(SMD，-3.09；95%CI，[-4.05，-2.13]；P<0.0001），肿瘤重量降低（SMD，-1.08；95%CI，[-1.37，-0.78]；P<0.0001），肿瘤数量减少(SMD，-2.16；95%CI，[-3.45，-0.86]；P=0.001），并延长了生存持续时间(SMD，实验动物为0.97；95%CI，[0.23，1.71]；P=0.01）。
结论：PRR在包括肝细胞癌在内的8种动物模型中显示出潜在的治疗效果，肺癌,肉瘤,膀胱癌,白血病,结肠癌,胶质母细胞瘤,还有胰腺癌.然而,纳入研究的质量和数量可能会影响阳性结果的准确性.在未来,需要更多高质量的随机对照动物实验进行荟萃分析.
